Tempus AI Faces Analyst Divergence Amid Insider Selling Spree

Tempus AI (TEM) shares slid 6.6% after JPMorgan Chase slashed its price target by 25% to $60, though maintaining a neutral stance. The genomic testing firm nonetheless posted an 83% revenue surge to $367.2 million in Q4, trouncing estimates.

Insiders unloaded $37.5 million worth of shares over 90 days, signaling potential profit-taking after the stock's 147% run since its June IPO. Analyst opinions split sharply: Mizuho initiated coverage with a street-high $100 target, while Stifel cut its outlook to $60, citing 'mixed profitability signals.'

The company's bold $1.59 billion 2026 revenue forecast suggests 25% annualized growth, banking on expansion in precision oncology diagnostics. Canaccord and Needham remain bulls, with $80 and $75 targets respectively, highlighting pharma sector demand.